Report Overview

The Gastrointestinal therapeutics market size in Kenya stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

According to World Health Organization (WHO), diarrhoea is one of the major causes of death among children under five years worldwide and it is classified as the second main cause of death. In Kenya, during the year 2018, 1,499,146 cases of diarrhoea were reported among children under five years. Among the cases of diarrhoea in 2018 in Kenya, Nairobi accounted for 136,028 cases. Risk Factors for Diarrhoea are contaminated drinking water, poor sanitation, personal hygiene, presence of open garbage or faeces near household and hand washing practice. Upper Gastrointestinal complaints among adults are common in Kenya. Peptic and Gastric ulcers are mainly caused by a bacterium - Helicobacter pylori. Inflammatory Gastrointestinal disorders like Ulcerative Colitis, Irritable/Inflammatory Bowel Syndrome may be attributed to lifestyle and dietary changes. Epidemiological surveys conducted in Kenya revealed high prevalence of Intestinal parasitic infections caused by Ascaris lumbricoides, Trichuris, Entamoeba histolytica, Giardia lamblia etc.



Market Drivers

The market is majorly driven by the rising burden of Gastrointestinal diseases in Kenya. A large proportion of Kenyas urban population live in slums with poor housing and sanitation. Living condition of urban slums is a major cause of diarrhoea among children and water-borne parasitic intestinal diseases.

Kenya is undergoing rapid urbanization and is among fastest growing economy in Eastern-Africa. Adoption of modern lifestyle and dietary changes in the urban population has led to increase in the incidence of inflammatory gastrointestinal disease like peptic ulcers and ulcerative colitis.

The prevalence of diarrhoea among children under five years in the households of urban informal settlements was 18.7%. High Prevalence of Diarrhoea and increasing incidence of inflammatory gastrointestinal diseases is expected to drive growth in the gastrointestinal therapeutics market in the forecast period.

However, low levels of awareness and increase in generic segment that is cost effective will lower the growth rate of the gastrointestinal therapeutics market.